VWD Study Opportunity - Velora Discover

 

A Prospective, Screening Study of Bleeding and Treatment in Participants With Von Willebrand Disease

 
 

An Observational Study Opportunity is available for individuals with Von Willebrand Disease (VWD). Chosen participants would primarily be required to journal their bleed experiences.  The study is sponsored by HEMAB Therapeutics, a company who has a therapeutic focus for VWD.

But availability is limited, so please apply quickly.

 
 

WHAT IS THIS?

An exciting new study is open for individuals with Von Willebrand Disease (VWD).

The study includes a:

  • Screener to apply

  • Baseline evaluation - involves onsite assessment & bloodwork

  • Observation period (approximately 4 months) which will include:

    • telemedicine from home (virtual or phone)

    • check-ins (every other week) to monitor bleed diary entries and bleeding event treatments

This stage of the study is strictly observational to record information regarding bleeding events, quality of life, and the social and clinical impact of bleeds.  No experimental medications will be administered.

Availability is limited, so those interested should apply at their earliest convenience by completing the screener.

This opportunity is for:

  1. Patients 16 years of age and older

  2. Participants diagnosed with, or suspected to have Von Willebrand Disease (VWD)

  3. Both men and women are encouraged to apply!


 

WHY PARTICIPATE?

There are many benefits

  • Fair-market compensation is provided for invested time of enrolled participants

  • Travel expenses will be compensated for those coming from any state outside of their assigned study sites (listed further down)

  • Participants who complete VELORA Discover will have the first opportunity to be involved in VELORA Pioneer, a study evaluating the treatment product, clinically named HMB-002 for infrequent subcutaneous therapy for VWD

  • An opportunity to Pay It Forward. Advancement of treatments are only made possible in-part by participants who join the fight. Generations before us are responsible for the medications readily available today. And only today’s generation can bring new, better treatments to a reality.

 

DATES

Enrollment is currently open and expected to close the summer of 2026 or until availability runs out.

 

LOCATIONS

Currently, 11 Hemophilia Treatment Centers throughout the United States are enrolling participants, with more to open.

 

  • Phoenix Children's Hospital

    Phoenix, Arizona, United States, 85016

  • Arkansas Children's Hospital

    Little Rock, Arkansas, United States, 72202-3591

  • Children's Hospital of Los Angeles (Not yet recruiting)

    Los Angeles, California, United States, 90027

  • University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center

    Miami, Florida, United States, 33136

  • Emory Children's Center

    Atlanta, Georgia, United States, 30329

  • Innovative Hematology, Inc./Indiana Hemophilia and Thrombosis Center

    Indianapolis, Indiana, United States, 46260

  • Tulane University School of Medicine

    New Orleans, Louisiana, United States, 70112-2699

  • University of Michigan Hospitals, Department of Hemophilia and Coagulation Disorders

    Ann Arbor, Michigan, United States, 48109

  • Mayo Clinic - Rochester

    Rochester, Minnesota, United States, 55905

  • Oregon Health & Science University

    Portland, Oregon, United States, 97239-3098

  • Hemophilia Center of Western Pennsylvania (Not yet recruiting)

    Pittsburgh, Pennsylvania, United States, 15213

  • The University of Texas Southwestern Medical Center

    Dallas, Texas, United States, 75390

  • Washington Institute For Coagulation (WIC)

    Seattle, Washington, United States, 98101 

 

APPLY NOW

SCREENER

Note: Qualifying participants must be chosen by the sponsor to participate.  There are no guarantees for admittance upon the conclusion of the screening process.  Please feel free to pass this message on to others who you think may qualify.

If you have trouble using the button above, or you have any further questions, you may email Eric Lowe directly at: elowe@ches.education